Safety Outcomes / Cardiovascular

(C-237) Assessing the Risk of Angioedema in Adult Sacubitril/Valsartan Users With Heart Failure: Results From a Post-Authorization Safety Study in Seven European Electronic Healthcare Databases

(C-231) Calcium Supplements and the Risk of CVD Recurrence: Real-World Evidence

(C-228) Cancer Treatment-Related Risk Factors for Stroke among Patients with Lung Cancer: A Systematic Review

(C-236) Comparative Postoperative Outcomes and Utilization Trends of Transcatheter Aortic Valve Implantation vs. Redo Surgical Aortic Valve Replacement

(C-233) Emulating a Clinical Trial to Assess the Fitness of Real-World Data for Evaluating the Cardiovascular Safety of Fixed-Dose Combination Naltrexone/Bupropion in the United States

(C-227) Evaluating The Risk of Arrhythmias in Patients With COPD Treated With Aclidinium and Aclidinium/Formoterol and Other Inhaled Bronchodilators

(C-230) Evaluating the Risk of Stroke among Female Patients using Osteoporosis Treatments

(C-240) Impact and Assessment of Medication Therapy Management Services on Oral Anticoagulants: A Patient-Centric Based Approach

(C-239) Incidence of Severe Uterine Bleeding Following Exposure to Non-Vitamin K Antagonist Oral Anticoagulants in South Korea

(C-234) Nonacute Opioid Use and Cardiovascular Risk in Peri- and Post- Menopausal Women: An Observational Cohort Study

(C-229) Osteoporosis Treatments and the Risk of Myocardial Infarction in Female Patients

(C-238) Potential Related Factors Influencing the Occurrence of CVD in Newly Diagnosed ADHD Patients

(C-235) Safety and Effectiveness of Anticoagulation in Cancer Patients with Venous Thromboembolism: A Population-based Cohort Study

(C-232) Thrombosis and Bleeding Risk in Patients Receiving NOACs and P-gp Inducers or Inhibitors: A Case-Case-Time-Control for Drug Interactions Assessment